Pere Mañé Takes the Helm as the New CEO of Suanfarma

Pere Mañé Takes the Helm as the New CEO of Suanfarma



Suanfarma, a major player in the pharmaceutical ingredient sector, has recently appointed Pere Mañé Godina as its new Chief Executive Officer (CEO). This change comes at a pivotal time for the company as it embarks on its mission to enhance industrial consolidation, sustainable innovation, and international growth. With this leadership transition, Suanfarma aims to position itself as a leader in high-value pharmaceutical services.

The decision to appoint Mañé reflects a robust strategic vision aimed at elevating Suanfarma to new heights within the global marketplace. His extensive background spanning over three decades in the pharmaceutical field adds significant value to the organization. Prior to joining Suanfarma, he held several key technical and leadership positions at notable companies like Uquifa, Boehringer Ingelheim, and Esteve Química (Esteve Group). His diverse expertise includes roles from operational management to executive leadership that have equipped him with a deep understanding of industry dynamics.

Mañé’s recent accomplishments include spearheading the industrial transformation efforts at Esteve, where he led initiatives that set its chemical division as a leading reference in the industry. His effective leadership was instrumental in Esteve being awarded the title of CDMO of the Year for Small Molecules at the prestigious DCAT 2025 Leadership Awards, cementing his reputation as a frontrunner in pharmaceutical innovation.

In this new chapter for Suanfarma, Mañé’s objectives will revolve around fundamental strategies like streamlining industrial operations, integrating emerging technologies, and enhancing engagement with global clients and suppliers. These priorities reflect an understanding of the market demands and the necessity for companies to adapt and grow in response to various challenges. Furthermore, Mañé emphasizes the importance of fostering a culture of sustainability and innovation throughout all operational levels.

Carlos Alonso, who has been serving as Suanfarma's interim CEO since October 2024, has played a vital role in ensuring a smooth leadership transition. He will continue to contribute to the company as Executive Chairman, providing guidance and support during this crucial changeover. His experience and insight will be invaluable as Suanfarma navigates the complexities of the pharmaceutical landscape under new leadership.

In his inaugural address, Mañé expressed enthusiasm for the future. "Suanfarma has all the elements to lead the future of the industry – a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team." He is looking forward to collaborating with the talented individuals at Suanfarma to continue delivering innovative, efficient, and sustainable solutions that meet the needs of clients across the globe.

Suanfarma, established in 1993, has made significant strides in the life sciences sector, focusing on health and innovation through the sustainable development, manufacturing, and distribution of high-quality pharmaceutical ingredients. Operating in over 70 countries, the company has been part of the healthcare-oriented investment firm Archimed since 2021, further solidifying its commitment to excellence within the global healthcare supply chain.

As Mañé steps into his role, the entire organization looks forward to an era marked by growth and positive change, leveraging his expertise to navigate future challenges and achieve remarkable feats in the ever-evolving pharmaceutical industry.

With Mañé's appointment, Suanfarma is poised to enhance its competitive edge, expand its market presence, and discover new avenues for growth, ultimately ensuring that it remains at the forefront of the pharmaceutical landscape for years to come.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.